tissue distribution

Retatrutide Pharmacokinetics and Tissue Distribution

Eli Lilly's 2023 Phase 2 trial data revealed how retatrutide's pharmacokinetics—specifically its absorption and extended half-life enabled by a fatty acid modification—allow weekly dosing despite targeting three hormone receptors simultaneously.